PharmaFocus Today – Page 10 – media

A rare disease company was acquired for $4.1 billion.

Italian pharmaceutical company Angelini Pharma recently announced its acquisition of Catalyst, a US-based rare disease specialist, for $4.1 billion, aiming to capitalize on the lucrative US market. The two companies expect to close the deal in the third quarter. According to publicly available information, Catalyst was founded in 2002 and went public on NASDAQ in 2006. The company is patient-centric, focusing on the introduction, development, and commercialization of novel medicines for rare and intractable diseases. In 2025, Catalyst’s revenue reached $589 million, a 20% increase, and this year’s revenue is projected to be between $615 million and $645 million. It has three products already on the market: Firdapse (amifampridine) is the company’s flagship product. It is the only evidence-based treatment approved by the FDA for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged 6 and older. Sales of this drug are projected to reach $358 million in 2025, a 17% year-on-year ...
- Source: drugdu
- 78
- May 12, 2026
Revenue Soars 34% — Why BeiGene Decisively Cut 6 Pipeline Programs?

On May 8, BeiGene officially released its Q1 2026 financial results. Against the backdrop of overall pressure on China’s innovative drug industry and increasingly intense competition in R&D and commercialization, the company’s revenue performance bucked the trend and exceeded market expectations. Even more striking and industry-shaking, the company simultaneously announced a major pipeline strategy adjustment — terminating six investigational programs at once, covering five hot oncology targets and one autoimmune disease pipeline, signaling a clear strategic retrenchment. This “amputation-style” strategic adjustment marks the official end of China’s innovative drug leader’s past “land-grab” expansion model, fully transitioning to a new stage of high-quality development centered on “precision focus, efficient investment, and quality first,” setting a benchmark for industry transformation. I. Core Products Continue to Drive Growth, Commercialization Capabilities Re-validated Key financial data shows that in Q1 2026, BeiGene’s global product revenue reached US$1.5 billion, a substantial 34% year-over-year increase, demonstrating strong ...
- Source: drugdu
- 117
- May 11, 2026
InxMed Bio Partners with Fosun Pharma — Deal Worth RMB 1.115 Billion

On May 8, 2026, InxMed Biotechnology (Nanjing) Co., Ltd. announced a strategic partnership with Fosun Pharma. Under the agreement, InxMed Bio will grant Fosun Pharma the exclusive rights for sales, promotion, and full-channel commercialization of its two self-developed innovative FAK inhibitors, IN10018 (Ifebemtinib) and IN10028, in mainland China (excluding Hong Kong, Macau, and Taiwan). As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance. As consideration, InxMed Bio will receive an upfront payment of RMB 100 million, plus milestone payments of up to RMB 1.015 billion tied to R&D registration and sales performance. IN10018 is an innovative small-molecule FAK inhibitor with dual regulatory functions — kinase catalytic and protein scaffold — that exerts anti-tumor effects through multiple mechanisms including oncogenic pathway modulation and inhibition of tumor proliferation and invasion. The product ...
- Source: drugdu
- 87
- May 11, 2026
China Biopharmaceutical’s world-first innovative breast cancer treatment drug approved for first-line treatment indication

On May 6, Cumoxicillin Capsules (Saitanxin®), the world’s first CDK2/4/6 inhibitor independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of China Biopharmaceutical (01177.HK), received approval from the National Medical Products Administration (NMPA) for its combination with fulvestrant for the initial treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This is the second indication approved for the marketing of Cumoxicillin Capsules, providing a new treatment option for first-line treatment of HR-positive advanced breast cancer patients in China. Last December, cumoxicillin was approved in combination with fulvestrant for the treatment of HR+/HER2- breast cancer patients whose disease has progressed after prior endocrine therapy, and it is estimated that it has already benefited thousands of breast cancer patients in clinical practice. This new approval is primarily based on the CULMINATE-2 clinical trial, which showed that cumoxicillin in ...
- Source: drugdu
- 105
- May 9, 2026
The Phase III monotherapy clinical trial of Lianhuan Pharmaceutical’s LH-1801 tablets has been unblinded.

On the evening of May 7th, Lianhuan Pharmaceutical…(600513) issued an announcement stating that the Phase III monotherapy clinical trial of the Class 1 new drug LH-1801 tablets organized by the company has been unblinded and preliminary analysis results of the main data have been obtained recently. The announcement indicates that LH-1801 tablets are a novel SGLT-2 inhibitor, developed by Lianhuan Pharmaceutical in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and possessing independent intellectual property rights in China.A new antidiabetic drug, indicated for type 2 diabetes. https://finance.eastmoney.com/a/202605073730257969.html
- Source: drugdu
- 92
- May 9, 2026
Shian Biotech and GSK reach licensing collaboration worth over $1 billion on oligonucleotide drugs

Recently , GlaxoSmithKline (GSK) and SiranBio (hereinafter referred to as “SiranBio”) reached a global exclusive licensing agreement for the investigational small interfering RNA (siRNA) oligonucleotide SA030. GSK will pay Shian Biotech an upfront payment and up to US$1.005 billion in development, registration and commercialization milestone payments, as well as tiered royalties based on global net sales (excluding mainland China, Hong Kong, Macau and Taiwan). SA030 is currently in Phase I clinical trials and targets activin receptor-like kinase 7 (ALK7) for the treatment of metabolic and cardiovascular diseases. Its design target avoids the weight loss market and targets the most difficult-to-treat abdominal visceral fat. According to International Pharmaceutical Business News, this is the second time in nearly six months that GSK has acquired siRNA assets from a Chinese biotechnology company. In the previous transaction, GSK acquired two siRNA drug candidates for respiratory, immune and inflammation (RI&I) fields from Frontier Biotechnologies for ...
- Source: drugdu
- 105
- May 9, 2026
Is CAR-T cells forming bubbles in the body?

Following its $2.4 billion acquisition of Orna Therapeutics earlier this year, Eli Lilly is once again betting heavily on in vivo CAR-T therapy. Recently, Eli Lilly announced its acquisition of Kelonia Therapeutics for $7 billion, pushing the valuation of transactions in the in vivo CAR-T field to a new high. This means that by 2026, Eli Lilly will have invested nearly $10 billion in the in vivo CAR-T field alone. It’s worth noting that this acquisition doesn’t involve mature assets. Kelonia’s core drug, KLN-1010, is still in Phase I, with only early validation completed in four patients. Orna’s core asset, ORN-252, is in the clinical trial preparation stage. Clearly, Eli Lilly is not betting on a single molecule, but rather on two differentiated in vivo CAR-T technology pathways. Orna uses an LNP delivery + circular RNA system, which has advantages in in vivo stability and sustained protein expression, making it ...
- Source: drugdu
- 87
- May 9, 2026
Product revenue reached RMB 10.3 billion, a year-on-year increase of 29%.

On May 6, 2026, BeiGene (NASDAQ: ONC; HKEX: 06160; SSE: 688235.SH) released its first quarter 2026 financial results. During the reporting period, the company’s total revenue was RMB 10.544 billion, representing a year-on-year increase of 31.0%. Product revenue accounted for 98% of total revenue, reaching RMB 10.321 billion, a year-on-year increase of 29.3%, mainly driven by sales growth of Brukinsa® (zanubrutinib), as well as Amgen’s licensed products and Tislelizumab®. The announcement shows that thanks to increased product revenue and improved cost management, the company’s operating efficiency has been further improved, with net profit attributable to the parent company reaching RMB 1.608 billion in the first quarter. In addition, BeiGene has adjusted its operating performance forecast for 2026, with total revenue now expected to be between RMB 43.6 billion and RMB 45.2 billion, up from between RMB 43.6 billion and RMB 45 billion. Full-year operating profit (i.e., operating revenue minus operating ...
- Source: drugdu
- 278
- May 9, 2026
Domestically produced autoimmune drugs are beginning to show their potential.

The emergence of domestically produced autoimmune drugs has come faster than expected. In 2024, four domestically produced autoimmune biological agents were approved, ending the previous “frozen” state of having no drugs and ushering in the first watershed moment. Hengrui Medicine, Connoya, Zhixiang Jintai… the names of domestic pharmaceutical companies began to appear on the autoimmune drug landscape. Accompanying this is a collective start for China to avoid “target differentiation and starting on the same track”. Globally, the autoimmune field is a breeding ground for blockbuster drugs, catalyzing the emergence of numerous multinational pharmaceutical companies (MNCs) with market capitalizations exceeding $100 billion. Currently, the performance of major pharmaceutical companies such as AbbVie, Sanofi, and UCB is still dominated by autoimmune single products. Just a few days ago, Sanofi’s Q1 2026 financial report showed that its flagship product, dupilumab, generated $4.874 billion in sales in a single quarter, representing a year-on-year increase ...
- Source: drugdu
- 86
- May 9, 2026
New breast cancer drug successfully completed Phase 3 trials.

Recently, Celcuity announced that its self-developed pan-PI3K/mTOR inhibitor gedatolisib achieved a clinically meaningful improvement in progression-free survival (PFS) in the Phase 3 clinical trial codenamed Viktoria-1 for advanced breast cancer. This Viktoria-1 clinical trial focused on patients with PIK3CA wild-type advanced breast cancer and employed a highly compelling head-to-head controlled design. The experimental group received triple therapy consisting of gedatolisib, AstraZeneca’s fulvestrant (Faslodex), and Pfizer’s palbociclib (Ibrance), while the control group received the current clinical standard of care—Novartis’ Piqray in combination with fulvestrant. had a statistically and clinically significant improvement in progression-free survival (PFS) . Furthermore, the dual therapy regimen of gedatolisib and fulvestrant also performed well in the key secondary endpoint compared to Piqray plus fulvestrant, validating its therapeutic advantage in this patient population. The release of this significant data quickly generated a positive response in the capital market. Following the announcement, Celcuity’s stock price surged nearly 40% in ...
- Source: drugdu
- 87
- May 8, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.